Treating Vision, Not Signs: A Post-hoc Analysis Evaluating

BCVA as an Early Indicator in Treat-and-Extend Management

of DME

Authors

Aly Hamza Khowaja MBBS[1,2], Kholood Janjua PharmD[2,3], Haider Ali MBBS[2], Rubbia Afridi MD

MPH[2,3], Zoha Zahid Fazal MBBS[2], Mohammad Abdul Saqhlain Shaik MSc[2], Mohamed Ibrahim

Ahmed MD MSc[3], Muhammad Sohail Halim MD MPH[2,3], Theodore Leng MD MS FACS[2],

Carolyn K. Pan MD[2], Quan Dong Nguyen MD MSc[2], Yasir Jamal Sepah MBBS[2,3]

Institutions

1.   Medical College, The Aga Khan University Hospital, Karachi, Sindh, Pakistan

2.   Ophthalmology, Stanford University Medicine, Palo Alto, California, United States

3.   Ocular Imaging Research and Reading Center, Sunnyvale, California, United States

Correspondence

Yasir Jamal Sepah, MBBS

Assistant Professor of Ophthalmology

Byers Eye Institute, Stanford University

2370 Watson Court, Palo Alto, CA 94303

Phone: +1 (323) 546-4772

Email: yjs@stanford.edu

Word count

3705 words

Keywords

ocular biomarkers, precision medicine, OCT, Central Retinal Thickness, anti-VEGF

Funding Information

This study was supported by the CDH grant and in part by NIH P30 core grant.

Disclosure

Acknowledgments

None.

Conflict of Interest

The authors have no conflict of interest to declare.

Financial Support

This study was supported by the CDH grant and in part by NIH P30 core grant.

Data Sharing Statement

The READ-3 dataset used as part of this study manuscript can be made available on

reasonable request.

Meeting Presentation

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9,

2024.

Abstract

Purpose

To determine whether significant changes in best-corrected visual acuity (BCVA) precede or

coincide with increases in central retinal thickness (CRT) in diabetic macular edema (DME)

during a treat-and-extend (T&E) regimen following initial edema resolution.

Methods

This post-hoc analysis included 60 eyes (60 participants) from the READ-3 clinical trial that

achieved CRT <250 μm and were followed until edema recurrence. Following a six-month

ranibizumab loading phase, patients were monitored through 24 months with as-needed

retreatment. Significant changes were defined as ≥4 Early Treatment Diabetic Retinopathy

Study (ETDRS) letters and ≥30 μm on time-domain optical coherence tomography (TD-OCT).

The temporal relationship between functional (BCVA) and anatomical (CRT) changes was

analyzed.

Results

Median time to edema resolution was 10 months (IQR: 6-16) and to recurrence was 3 months

(IQR: 2-3). 52 eyes (86.7%) had functional worsening and 43 (71.7%) had anatomical

worsening. In 39 eyes exhibiting both types of deterioration, changes were concurrent in 24

(61.5%). Vision loss preceded anatomical recurrence (BCVA-led) in 23.1% of eyes, with a lead

time of 1-4 months. Conversely, anatomical thickening preceded vision loss (OCT-led) in 15.4%

of eyes, by a maximum of 2 months.

Conclusions

BCVA fluctuations frequently mirror CRT changes and can precede structural relapse,

suggesting that BCVA is a sensitive indicator of DME activity. In resource-limited settings,

BCVA may allow for earlier detection of recurrence than OCT alone.

Translational Relevance

Functional vision loss can precede structural edema recurrence, supporting the potential for

home-based BCVA monitoring as a validated bridge for timely clinical intervention in DME.

Introduction

Diabetic macular edema (DME) is a leading cause of preventable vision loss among working-age individuals with diabetic retinopathy (DR)[1]. The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized DME management, yielding significant visual gains in clinical trials. Historically, regulatory approval and trial endpoints have centered on functional improvements, specifically best-corrected visual acuity (BCVA) gains[2,3]. However, in routine practice ophthalmologists often rely on optical coherence tomography (OCT) findings, such as changes in central retinal thickness (CRT) or central subfield thickness, to guide re-treatment. This shift toward anatomical endpoints reflects the assumption that retinal thickening correlates with, and even precedes, vision loss[4].

In reality, the structure-function relationship in DME is complex and variable. Not all patients experience parallel improvements in BCVA and CRT. Real-world data suggest that fewer than 25% of eyes achieve both a dry macula and BCVA 20/40 after nine anti-VEGF injections[5]. Such misalignment means some patients have persistent vision impairment despite resolved edema, while others maintain good vision despite residual edema. If physicians treat based solely on OCT abnormalities, patients might receive injections even when functional vision is stable. This discordance can lead to overly aggressive treatment schedules and increases the burden of frequent clinic visits and injections on patients and healthcare systems. Conversely, monitoring primarily by OCT may delay detection of functional decline in cases where BCVA worsens before obvious OCT changes. In such scenarios, insisting on costly, monthly OCT monitoring for every patient may become impractical.

While the technological precision of OCT is undeniable, the current over-reliance on anatomical endpoints risks distancing clinicians from patients' primary concern: vision. By recentering management around visual acuity, we align treatment triggers with the patient's lived experience

rather than treating isolated tomographic signs. There is thus a pressing need for practical

monitoring solutions that can detect disease activity as a timely and patient-centric alternative

without over-reliance on clinic-based OCT. We hypothesize that clinically meaningful changes in

BCVA (≥4 ETDRS letters) might serve as an early indicator of DME activity, occurring

concurrently with or even ahead of CRT changes, including in eyes that have been successfully

treated to resolution of edema. To explore this hypothesis, we performed a post-hoc analysis of

the READ-3 (Ranibizumab for Edema of the mAcula in Diabetes, Protocol 3) trial[6] – a

prospective, multicenter DME study with high-frequency OCT and BCVA follow-up. By analyzing

the lag between functional and anatomical changes during a treat-and-extend protocol, we

tested whether clinically meaningful BCVA changes (≥4 ETDRS letters) precede, coincide with,

or follow OCT-detected CRT increases after initial macular drying, which has implications for

monitoring strategies and resource allocation. We also considered the implications for a home-

based BCVA monitoring system that could complement or substitute for OCT in routine DME

management.

Methods

Study Design and Population

This is a post-hoc analysis of READ-3, a 24-month randomized clinical trial conducted at 13

U.S. sites. The trial enrolled adults with DME meeting typical inclusion criteria, including

baseline CST ≥250 µm on time-domain OCT and BCVA 20/40 to 20/320 (ETDRS letters). Key

exclusion criteria were recent macular laser or intraocular steroid, or anti-VEGF treatment within

2–3 months. Each patient contributed one study eye; if both were eligible, the eye with greater

CRT was selected. All participants provided informed consent, and the study adhered to the

Declaration of Helsinki and was registered on clinicaltrials.gov (NCT01077401)[7].

Treatment Protocol

Enrolled eyes were randomized 1:1 to monthly intravitreal ranibizumab 0.5 mg or 2.0 mg for six

consecutive months (baseline through Month 5). The month 6 visit, which was also the primary

endpoint of the trial occurred 4 weeks after the sixth injection.[6] At and beyond Month 6, treat-

and-extend management was implemented: patients were evaluated monthly and received

additional ranibizumab injections only if OCT showed recurrent macular edema (central subfield

thickness ≥250 µm on time-domain OCT (TD-OCT), or any macular fluid detected on time-

domain or spectral-domain OCT). If no edema was present, the injection could be deferred, and

the patient examined again the following month. (Note: This regimen is effectively a pro re nata

(PRN, as-needed) approach with monthly monitoring; for simplicity we refer to it as "treat-and-

extend," although no fixed extension interval was predetermined beyond monthly

evaluations.) All study visits included BCVA measurement (following ETDRS protocol[8] by

certified examiners), OCT imaging, and ophthalmic examinations.

Study Cohort and Inclusion Criteria

We identified eyes that achieved complete resolution of edema at any visit after the mandatory

monthly loading dose visits, defined as CRT <250 µm with no intraretinal or subretinal fluid

visible on OCT. For this analysis, the first occurrence of an "edema-free" retina, as well as

documented evidence of deferred injection, was considered the start-point, or the eligibility visit,

for each eye. Included eyes were followed from this visit to the recurrence of edema and

retreatment. Eyes that (1) did not achieve edema resolution; (2) did not have edema recurrence

following treatment; (3) were treated pro-actively before evidence of recurrence, were all

excluded from analysis.

Outcome Measures

For the present analysis, we tracked two main outcomes: (1) Lag between functional and

anatomical changes, specifically, whether BCVA changes occurred before, at the same time, or

after corresponding CRT changes; and (2) Injection-free interval: the duration each eye

remained in the "treat-and-extend" phase of deferred re-injection after eligibility, which reflects

how long edema stayed in remission.

Definitions

We defined the eligibility visit as the first visit for each patient that saw the concurrence of CRT

<250 μm with no intraretinal or subretinal fluid visible on TD-OCT and deferral of injection. By

protocol definition, this could only occur after completion of the initial loading phase of

mandatory injections.   A clinically significant BCVA change was defined as a gain or loss of ≥4

letters from the previous visit (approximately equivalent to ≥0.08 logMAR change), based on

test-retest variability of ETDRS charts and prior definitions of meaningful change.[9] A significant

CRT change was defined as an increase or decrease of >30 μm on TD-OCT, consistent with

thresholds used in DME studies for meaningful edema fluctuation. A BCVA–CRT or 'B-C'

lag was said to occur if a significant change in BCVA was not observed in the *same* visit as a

significant change in CRT for that eye. In other words, if one parameter changed at visit *n* and

the other changed at a later visit *n+x* (or had changed earlier at *n–x*), we considered a lag

of *x* months to be present. By this definition, we classify as BCVA-leading cases those where

BCVA   change   came   first, CRT-leading cases   those   where   CRT   changed   first,

and concurrent cases those where both changed in the same month (lag = 0). Eyes that only

met the criteria for one parameter (missing either significant BCVA or CRT worsening during

follow-up, but not both) were tracked as well.

Data Analysis

We summarized baseline patient characteristics and the distribution of lag categories using

descriptive statistics. For each eye, the timing (months) of the first occurrence of significant

functional change (≥4-letter drop in BCVA) and significant anatomical change (≥30 μm rise in

CRT) during the eligible study interval was recorded. Eyes were then categorized by the

temporal sequence of these events: BCVA change preceding CRT change, simultaneous

change, CRT change preceding BCVA change, or no significant event. All statistical tests were

2-tailed with a significance level of α=0.05. Analyses were performed using Stata 15.1

(StataCorp, College Station, TX).

Results

Cohort Identification

Of the 155 eyes in the READ-3 trial, 81 eyes reached at least one edema-free event. 21 of

these eyes had re-injection before any change in BCVA or any change on OCT could be

observed. The 60 eyes with changes in at least one parameter were hence identified. A further

subset of 39 eyes with changes on both, OCT and BCVA, was also identified. The process is

depicted as **Figure 1.**

Figure 1. Flow diagram illustrating the identification of eligible eyes for inclusion in this

analysis.

Patient Characteristics and Disease Activity

The 60 patients had a mean age of 65.0 ± 11.0 years; 48.3% were female (29/60). All had type

1 or type 2 diabetes with DME and had received treatment as per protocol. At baseline, the

mean CRT was elevated (413.9 ± 126.8 µm) and BCVA was moderately impaired (58.6 ± 10.4).

At eligible visit, mean CRT improved substantially (196.9 ± 30.6 µm) and BCVA improved by ~8

letters (66.1 ± 13.8) . Mean BCVA and CRT values can be found in **Table 1.** All 60 eyes had

CRT <250 µm at eligibility, confirming complete edema resolution. The median time to eligibility

was 10 months (IQR 6-15.5) and the median number of injections prior to eligibility was 8.5

(IQR: 6-13.5), including the six mandatory injections as per protocol.

	Baseline	Eligibility Visit	Last Study Visit
Mean BCVA, (letters)	58.6 ± 10.4	66.1 ± 13.8	66.1 ± 13.1
Mean CRT (µm)	413.9 ± 126.8	196.9 ± 30.6	226.5 ± 84.4
Anatomical Success, n (%) CRT < 250µm	2 (3.3%)	60 (100%)	41 (68.3%)

Table 1. Summary of mean BCVA and CRT at 3 key study intervals: Baseline (month 0),

Eligibility visit (month 6-22), Last Study Visit (month 11-24)

Recurrence, Retreatment, and Clinical Management

The 60 eyes were followed monthly as per READ-3 protocol, for edema recurrence. In this

cohort, functional worsening, defined as a reduction in BCVA, was the most frequent indicator,

occurring in 52 eyes (86.7%). Anatomical worsening was detected by TD-OCT in 43 eyes

(71.7%). 39 eyes (65.0%) demonstrated both, a reduction in BCVA and an increase in CRT on

TD-OCT.

Re-injection was performed in 55 of the 60 eyes (91.7%). In the remaining five instances (8.3%),

retreatment was deferred despite objective changes in OCT or BCVA based on clinical

discretion. The retreated eyes received multiple additional reinjections after initial resolution, till

the conclusion of READ-3's 24-month endpoint (median number of injections = 4, IQR: 3-9.5).

For the 55 eyes that were retreated, no statistically significant difference in mean BCVA was

seen between BCVA at eligibility visit of edema resolution and retreatment visit (p = 0.16), or

eligibility visit and final BCVA at the end of the study period (p = 0.21).

In the group of 21 eyes where a temporal relationship between anatomy and function could not

be established, 13 (61.9%) had no detectable CRT changes while 8 (38.1%) had no BCVA

changes before the decision to continue treatment. The treatment, a prophylactic measure,

likely helped maintain a dry macula and stable vision. In those cases, we did not observe a lag

because neither parameter crossed the pre-specified threshold (these eyes can be considered

"censored" in time-to-event analyses).

Anatomical-Functional Lag

The temporal relationship between structural and functional decline, illustrated in Figure 2, was

analyzed in the subset of 39 eyes that experienced worsening in both parameters. In 24 eyes

(61.5%), the peak anatomical worsening and functional vision loss were detected at the same

visit (Lag = 0). In 9 eyes (23.1%), functional vision loss preceded anatomical recurrence (range:

1-4 months), while OCT changes preceded BCVA change in 6 eyes (15.4%), where anatomical

thickening was detected 1 to 2 months (not more) prior to observed vision loss. Cumulatively,

functional changes (BCVA) either preceded or coincided with anatomical recurrence in 84.6% of

cases, while anatomical changes (OCT) either preceded or coincided with functional

deterioration in 76.9% of cases.

217
Figure 2. Patient-level timelines of significant BCVA and CRT changes during the analysis

period. Each row represents one eye. Highlighted in green are occurrences where concurrent

changes in BCVA and OCT were seen. Those highlighted in blue represent OCT-led cases,

while those in red represent BCVA-led cases. Only cases with changes on both OCT and BCVA

are represented. ✚ eligibility visit; ★ significant change on TD-OCT (≥30 μm); ● significant

BCVA change (≥4-letter); ✪ concurrent BCVA and OCT change.

Discussion

Our post-hoc analysis of the READ-3 trial under a treat-and-extend paradigm provides intriguing

evidence that BCVA monitoring can serve as an early and independent indicator of disease

activity in DME. In a cohort of patients who had achieved a dry macula, we observed that BCVA

changes often paralleled or even anticipated structural changes during follow-up. Notably,

23.1% (9/39) showed functional deterioration (vision loss) *preceding* any OCT-detectable fluid

recurrence, in some cases by several months. This finding raises the possibility that, for select

patients, declining BCVA alone could signal impending edema relapse well before OCT

confirms it. To our knowledge, this is one of the first analyses to explicitly demonstrate such a

lag in DME after initial successful therapy. It challenges the common assumption[10] that

"anatomical changes precede functional declines" in all cases of DME and highlights a subset

where the opposite is true.

At the same time, our results reinforce that BCVA and OCT outcomes do not always move in

lockstep. We saw examples of eyes maintaining good vision for a while despite OCT recurrence

(CRT-led cases), as well as eyes with vision loss out of proportion to OCT findings. These

scenarios underscore the multifactorial nature of DME: factors like photoreceptor damage,

macular ischemia, or duration of edema can affect BCVA recovery independently of central

thickness[3,11]. Prior studies have shown strong correlation between OCT and BCVA findings at

baseline visits, but the correlation loses significance at subsequent study visits.[12] Such

discordances are not unique to DME; studies in retinal vein occlusion and uveitic macular

edema have reported that OCT changes and BCVA gains can diverge, especially in the short

term[13–16]. Our data in DME align with those reports, emphasizing the need for clinicians to

monitor both aspects. In practice, improvement in CRT without commensurate BCVA

gain should prompt a search for other limiting factors (e.g., retinal atrophy or diabetic cataract),

while BCVA decline without OCT changes should raise suspicion for early relapse or alternative

pathology (e.g., subtle vitreo-macular interface changes or capillary non-perfusion).

Crucially, because BCVA is the gold standard for visual function, these findings support a

greater role for BCVA-driven monitoring in DME management. With today's technology, if a

patient-used home monitoring system detects an early BCVA drop, even a small but significant

one, clinicians could intervene sooner – potentially preventing more serious edema build-up or

irreversible neuroretinal damage. In our series, earlier intervention at the point of BCVA decline

(rather than waiting for OCT confirmation) might have reduced the duration of edema in BCVA-

leading eyes, possibly preserving a few letters of acuity that were lost. This concept dovetails

with the DRCR Retina Network's Protocol V findings[17], where observation (no immediate

treatment) in center-involved DME with good vision was found to be safe in the short term. That

study suggested some eyes can tolerate edema without vision loss, but it also underscored the

importance of close follow-up: patients were monitored regularly and treated if BCVA worsened.

Our results extend this idea that monitoring BCVA closely is not only an option when initial

vision is good, but also a potentially sensitive way to catch recurrences in a treat-and-extend

scenario.

From a health systems perspective, we make the case to further study the potential of home-

based BCVA monitoring, especially as we move toward longer-lasting DME treatments. While

home OCT devices are being developed (e.g., home OCT for age-related macular

degeneration),[18] these are costly and require advanced technology and infrastructure. By

contrast, BCVA testing needs only a reliable method to display optotypes at the correct size and

distance. There are already proof-of-concept studies[19,20] suggesting feasibility: small trials have

shown that smartphone-based vision check apps can achieve near-clinic accuracy in measuring

visual acuity under controlled conditions. If BCVA can indeed detect meaningful changes earlier

in some patients, a reliable home test could prompt timely clinic visits or even telemedicine

consultations for OCT and treatment. In effect, BCVA-based home monitoring, augmented by

telemedicine, could shift care toward a more proactive and patient-centered model.

Despite proof-of-concept studies, no current app is scientifically validated or strictly adheres to

ETDRS protocol. If an FDA-approved home vision test could replicate standardized 4-meter

ETDRS acuity (perhaps via a smartphone app or a simple device) and securely transmit data to

clinicians, it would dramatically reduce the need for patients to come in solely for monitoring.

This is particularly pertinent for DME patients, who often represent a younger, working-age

population struggling to balance a high individual healthcare burden. These patients frequently

manage multiple comorbidities requiring visits across various clinical specialties, making the

flexibility of home monitoring essential. However, rigorous validation is essential to ensure the

future of home monitoring lies not in casual app use but is scientifically validated to distinguish

true pathological decline from test variability.

This prioritization of functional monitoring is not only clinically prudent for treat-and-extend

protocols in high-resource settings but is essential for global health equity. The simplicity and

low cost of BCVA testing have particular relevance to low- and middle-income countries

(LMICs), where OCT availability is limited. Prioritizing validated BCVA-based surveillance could

enable earlier detection of functional decline without requiring high-cost imaging, allowing

utilization of imaging resources for patients with demonstrable vision loss. We explicitly note

'LMICs' to highlight the global health relevance of function-first monitoring strategies. This shift

promotes a more sustainable and equitable model of eye care.

The timing of monitoring is another consideration. Our data reinforce that monthly

assessments are valuable – all our lag calculations were based on monthly intervals, and it was

within monthly visits that these changes were captured. This aligns with the standard loading

phase frequency and early extension phase in DME treatment, where monthly check-ins are

common until stability is achieved. The DRCR Network has shown that after initial stabilization,

follow-up intervals can be personalized (lengthened or shortened) based on disease activity[3].

Our results add that while some patients may not need monthly OCT once stable, monthly

BCVA self-checks could still be prudent to detect any functional slippage between infrequent

office visits. In high-resource settings, such data could refine treat-and-extend injection intervals

(e.g., calling patients back sooner if home acuity drops). In lower-resource settings, monthly

home BCVA monitoring could be a stopgap for those who cannot afford frequent clinic OCT – a

significant public health advantage given the global diabetes epidemic.

In conclusion, while both BCVA and OCT remain invaluable for managing DME, our analysis

suggests that BCVA can function as an early warning signal of disease reactivation in a

significant subset of patients. Developing an accurate home-based BCVA monitoring system

can transform accessible and proactive DME care. Our data support the notion that a four-week

(monthly) monitoring interval is clinically meaningful for capturing the interplay between vision

and retinal structure. Bridging the gap between clinic and home, BCVA-guided monitoring

(supplemented by OCT as needed and expert oversight) may ultimately improve outcomes and

reduce treatment burden in DME. As we move toward longer-lasting treatments and seek to

globalize care, leveraging the simplicity and scalability of visual acuity measurement offers a

promising avenue to ensure that no decline in vision goes unnoticed.

Study Limitations

We acknowledge several limitations to this analysis. First, the study is a retrospective post-hoc

analysis of a relatively small subgroup (n=60) from a single clinical trial. The findings, while

hypothesis-generating, may not generalize to all DME patients. READ-3 had rigorous monthly

follow-up and ETDRS vision testing[7]; real-world settings with less frequent visits or non-ETDRS

acuity measurements might yield different results. Second, our definition of "significant" change

(4 letters, 30 μm) was chosen based on practical thresholds, but various studies suggest

different criteria and an interplay of multiple factors. It's possible that micro-fluctuations in BCVA

or CRT not meeting our criteria could precede larger changes. SD-OCT and Swept-Source OCT

could be more sensitive in detecting anatomical changes and yield different results.

Third, confounding factors could influence BCVA independent of macular edema – for example,

cataract progression could cause a slow BCVA decline unrelated to retinal thickening.

Additionally, factors such as the duration of disease, HbA1C levels, and age further confound.[21]

We attempted to attribute BCVA changes to DME by requiring concurrent or subsequent edema

to label an event, but we cannot fully exclude other causes of vision change. Fourth, our treat-

and-extend regimen was effectively monthly PRN monitoring; thus, some eyes received

injections before relapse (preventing observation of a natural lag in those cases). While this

reflects real clinical practice, since physicians often treat preemptively, it means we had to

exclude 21 eyes as "no observable change" when in fact they might have relapsed if we had

waited longer. This could bias the proportions of lag categories. A prospective study that

withholds treatment until certain criteria are met might better quantify true lag frequencies but

would raise ethical questions. Finally, our analysis of correlation and visual outcomes was

limited by sample size, precluding definitive conclusions about long-term vision impact. The

observation that vision was generally recoverable after retreatment should be interpreted

cautiously; a larger dataset is needed to confirm that no harm comes from waiting for OCT

changes if BCVA has already dropped.

Implications and Future Directions

Despite these limitations, our findings support a paradigm shift wherein BCVA is not merely an

outcome measure but a practical monitoring tool in DME. We envision a future DME

management algorithm where patients use a certified home vision test weekly or monthly, and

any confirmed BCVA decline triggers a prompt clinic evaluation (or perhaps even direct

scheduling of an injection, if corroborated by other data). This could reduce unnecessary visits

(for those doing well) and catch relapses sooner, optimizing treatment timing. Importantly, this

approach aligns with the fact that regulatory approvals for DME therapies hinge on BCVA

improvement; it makes sense to also use BCVA to guide day-to-day management, keeping the

focus on what ultimately matters: the patient's vision. With longer-acting drugs reducing visit

frequency, such a scheme becomes even more attractive – with fewer clinic visits overall, and

those that do occur are prompted by a real indication of change. To realize this vision, further

research is needed. A prospective trial could test a BCVA-monitored strategy against an OCT-

monitored strategy, measuring outcomes like number of clinic visits, injections given, vision loss

prevented, and patient quality-of-life. Additionally, developing robust, user-friendly home BCVA

testing technology is paramount. Integrating these tools with telemedicine platforms and

electronic health records would allow seamless alerts to providers when a patient's acuity

crosses a threshold. Artificial intelligence could further assist by analyzing trends and false

positives/negatives in patient-reported data.

Conclusion

In summary, this post-hoc analysis of READ-3 highlights that clinically meaningful BCVA

changes can coincide with or precede OCT changes in the management of DME. A subset of

patients showed vision loss as the first sign of relapse, underscoring that BCVA is not merely a

passive outcome but can be an active monitoring tool. Given practical considerations of cost,

access, and patient burden, remote BCVA assessment strategy could substantially enhance

DME monitoring. Our findings provide proof of concept that monthly observation of BCVA (even

without OCT) can yield actionable information – potentially enabling timely retreatment and

preventing avoidable vision loss. BCVA-guided decision-making, combined with clinical

judgment and periodic OCT as needed, may thus represent a reliable and efficient strategy for

long-term DME care. Further prospective studies are warranted to validate these findings,

compare functional vs. anatomical monitoring protocols, and explore additional functional

markers. By advancing vision-monitoring tools and incorporating them into treat-and-extend

regimens, we can move toward a more patient-centric, scalable model of DME management

that maintains vision and quality of life for millions at risk.

References

1. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of
retinopathy in the diabetes control and complications trial. *Diabetes.* 1995;44(8):968-983.

2. Intravitreal Aflibercept for Diabetic Macular Edema - Ophthalmology. Accessed July 13, 2025.
https://www.aaojournal.org/article/S0161-6420(14)00426-6/fulltext

3. Tang T, Tran D, Han D, Zeger SL, Crews DC, Cai CX. Place, Race, and Lapses in Diabetic
Retinopathy Care. *JAMA Ophthalmol*. 2024;142(6):581-583.
doi:10.1001/jamaophthalmol.2024.0974

4. The Relationship between OCT-measured Central Retinal Thickness and Visual Acuity in
Diabetic Macular Edema. *Ophthalmology*. 2007;114(3):525-536.
doi:10.1016/j.ophtha.2006.06.052

5. Blinder KJ, Dugel PU, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in
clinical practice: effectiveness and patterns of use (ECHO Study Report 1). *Clin Ophthalmol
Auckl NZ*. 2017;11:393-401. doi:10.2147/OPTH.S128509

6. Do DV, Sepah YJ, Boyer D, et al. Month-6 primary outcomes of the READ-3 study
(Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). *Eye Lond
Engl*. 2015;29(12):1538-1544. doi:10.1038/eye.2015.142

7. Johns Hopkins University. *Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With
High Dose - the READ 3 Study*. clinicaltrials.gov; 2017. Accessed July 13, 2025.
https://clinicaltrials.gov/study/NCT01077401

8. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics.
ETDRS report number 7. *Ophthalmology*. 1991;98(5 Suppl):741-756. doi:10.1016/s0161-
6420(13)38009-9

9. Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen
for diabetic macular oedema: the RETAIN study. *Br J Ophthalmol*. 2016;100(6):787-795.
doi:10.1136/bjophthalmol-2015-307249

10.   Zhang CH, Gong B, Huang C, et al. Morphological and functional changes in the
macular area in diabetic macular edema after a single intravitreal injection of aflibercept. *Int J
Ophthalmol*. 2023;16(1):88-94. doi:10.18240/ijo.2023.01.13

11.   Moon BG, Um T, Lee J, Yoon YH. Correlation between Deep Capillary Plexus Perfusion
and Long-Term Photoreceptor Recovery after Diabetic Macular Edema Treatment.
Ophthalmol Retina. 2018;2(3):235-243. doi:10.1016/j.oret.2017.07.003

12.   Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, et al.
Relationship between optical coherence tomography-measured central retinal thickness and
visual acuity in diabetic macular edema. *Ophthalmology*. 2007;114(3):525-536.
doi:10.1016/j.ophtha.2006.06.052

13.   Yiu G, Welch RJ, Wang Y, Wang Z, Wang PW, Haskova Z. SD-OCT Predictors of Visual
Outcomes after Ranibizumab Treatment for Macular Edema due to Retinal Vein Occlusion.
Ophthalmol Retina. 2020;4(1):67-76. doi:10.1016/j.oret.2019.08.009

14.   Sen P, Gurudas S, Ramu J, et al. Predictors of Visual Acuity Outcomes after Anti–
Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central
Retinal Vein Occlusion. *Ophthalmol Retina*. 2021;5(11):1115-1124.
doi:10.1016/j.oret.2021.02.008

15.   Iannetti L, Scarinci F, Alisi L, et al. Correlation between Morphological Characteristics of
Macular Edema and Visual Acuity in Young Patients with Idiopathic Intermediate Uveitis.
Medicina (Mex). 2023;59(3):529. doi:10.3390/medicina59030529

16.   Matas J, Llorenç V, Fonollosa A, et al. Predictors for functional and anatomic outcomes
in macular edema secondary to non-infectious uveitis. *PLoS ONE*. 2019;14(1):e0210799.
doi:10.1371/journal.pone.0210799

17.   Baker CW, Glassman AR, Beaulieu WT, et al. Effect of Initial Management With
Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With
Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A
Randomized Clinical Trial. *JAMA*. 2019;321(19):1880-1894. doi:10.1001/jama.2019.5790

18.   Heier JS, Liu Y, Holekamp NM, et al. Clinical Use of Home OCT Data to Manage
Neovascular Age-Related Macular Degeneration. *J Vitreoretin Dis*. 2025;9(2):158-165.
doi:10.1177/24741264241302858

19.   Karampatakis V, Almaliotis D, Talimtzi P, Almpanidou S. Design and Validation of a Novel
Smartphone-Based Visual Acuity Test: The K-VA Test. *Ophthalmol Ther*. 2023;12(3):1657-
1670. doi:10.1007/s40123-023-00697-x

20.   Bastawrous A, Rono HK, Livingstone IAT, et al. Development and Validation of a
Smartphone-Based Visual Acuity Test (Peek Acuity) for Clinical Practice and Community-
Based Fieldwork. *JAMA Ophthalmol*. 2015;133(8):930-937.
doi:10.1001/jamaophthalmol.2015.1468

21.   Bressler SB, Odia I, Maguire M, et al. Factors Associated With Visual Acuity and Central
Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular
Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized
Clinical Trial. *JAMA Ophthalmol*. 2019;137(4):382. doi:10.1001/jamaophthalmol.2018.6786